Meme kanserli hastalarda kemoterapiye bağlı venöz tromboemboli
Amaç: Bu çalışmada venöz tromboembolinin (VTE) kemoterapi uygulanan meme kanserli hastalardaki klinik özellikleri incelendi. Çalışma planı: Ocak 2008 - Aralık 2012 tarihleri arasında Ondokuz Mayıs Üniversitesi Tıp Fakültesi Onkoloji Kliniğinde evre 1, 2 veya 3 meme kanseri tanısı konulan ve ameliyat sonrası nüksü önleme amaçlı kemoterapi uygulanan 500 kadın hasta çalışmaya alındı. Elde edilen tüm veriler, Ondokuz Mayıs Üniversitesi Tıp Fakültesi Kalp ve Damar Cerrahisi Kliniği uzmanları tarafından değerlendirildi. Bulgular: Medyan yaşı VTE geçiren hastalarda 70 yıl (dağılım, 32-76 yıl) iken, VTE geçirmeyen hastalarda 48 yıl (dağılım, 23-76 yıl) idi. On bir hastada (%2.2) VTE saptandı. Tromboemboli geçiren hastalarda medyan yaş daha yüksek idi (p
Chemotherapy-induced venous thromboembolism in patients with breast cancer
Background: This study aims to investigate the clinical presentation of venous thromboembolism (VTE) in patients with breast cancer undergoing chemotherapy. Methods: Between January 2008 and December 2012, 500 women who were diagnosed with grade 1, 2 or 3 breast cancer and underwent postoperative chemotherapy to prevent recurrences at Ondokuz Mayıs University, Faculty of Medicine, Department of Oncology were included. All data were reviewed by the experts at Ondokuz Mayıs University, Faculty of Medicine, Department of Cardiovascular Surgery. Results: The median age was 70 years (range, 32 to 76 years) in patients with VTE and 48 years (range, 23 to 76 years) in patients without VTE. Eleven patients (2.2%) had VTE. The median age was higher in patients with thromboembolism (p
___
- 1. Özyılkan Ö, Yıldırım Y. Kanserin tromboembolik komplikasyonları ve tedaviye yönelik yaklaşımlar. Acta Oncologica Turcica 2009;42:86-91.
- 2. Chavez-MacGregor M, Zhao H, Kroll M, Fang S, Zhang N, Hortobagyi GN, et al. Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer. Ann Oncol 2011;22:2394-402. doi: 10.1093/ annonc/mdq777.
- 3. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003;107:I17-21.
- 4. American Cancer Society. Breast cancer facts and figures 2007-2008. Atlanta, GA: American Cancer Society; 2009.
- 5. Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007;25:70-6.
- 6. Clahsen PC, van de Velde CJ, Julien JP, Floiras JL, Mignolet FY. Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study. J Clin Oncol 1994;12:1266-71.
- 7. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-9.
- 8. Sarıgül A, Tanyeli Ö. Derin ven trombozunda güncel tedavi yaklaşımları. Turk Gogus Kalp Dama 2007;15:316-21.
- 9. Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol 2001;106:6-12.
- 10. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404-7.
- 11. Mandala M, Falanga A, Labianca R. Video meliora proboque sed deteriora sequor: the case of thromboprophylaxis in hospitalized cancer patients. Ann Oncol 2010;21:911-3. doi: 10.1093/annonc/mdp500.
- 12. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-94.
- 13. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 1984;54:1264-8.
- 14. Kirwan CC, McDowell G, McCollum CN, Kumar S, Byrne GJ. Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. Br J Cancer 2008;99:1000-6. doi: 10.1038/sj.bjc.6604620.
- 15. Canobbio L, Fassio T, Ardizzoni A, Bruzzi P, Queirolo MA, Zarcone D, et al. Hypercoagulable state induced by cytostatic drugs in stage II breast cancer patients. Cancer 1986;58:1032-6.
- 16. Nolan L, Darby A, Boleti K, Simmonds P. The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer. Breast 2011;20:151-4. doi: 10.1016/j. breast.2010.09.001.
- 17. Sud R, Khorana AA. Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. Thromb Res 2009;123 Suppl 4:S18-21. doi: 10.1016/S0049- 3848(09)70137-9.
- 18. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902- 7. doi: 10.1182/blood-2007-10-116327.
- 19. Hall IE, Andersen MS, Krumholz HM, Gross CP. Predictors of venous thromboembolism in patients with advanced common solid cancers. J Cancer Epidemiol 2009;2009:182521. doi: 10.1155/2009/182521.
- 20. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-8.
- 21. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-83.
- 22. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53.
- 23. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729-35.